Page 24 of the March 7, 2016 presentation. Look
Post# of 30066
Posted On: 03/09/2016 6:32:31 PM
Page 24 of the March 7, 2016 presentation.
Looks like Ravi Kiron may have generated interest in Lympro, just that potential customers saw Amarantus' financial status could be a possible detriment to trials.
Combining the dx with a revenue producing lab that is already working with these potential customers could be a really big win, especially if Gregg Linn does actually get solid financing. Not sure where that leaves shareholders of AMBS.
http://content.stockpr.com/amarantus/db/184/1...+FINAL.pdf
Looks like Ravi Kiron may have generated interest in Lympro, just that potential customers saw Amarantus' financial status could be a possible detriment to trials.
Combining the dx with a revenue producing lab that is already working with these potential customers could be a really big win, especially if Gregg Linn does actually get solid financing. Not sure where that leaves shareholders of AMBS.
Quote:
Business Case for LymProTest® Pharma Services in Alzheimer’s disease
Interest created from 2014-2015 from same customer list as Theranostics Health
Major challenges
-Overall business focus shifted towards therapeutics
-Scarcity of resources forced Amarantus to devote majority towards diagnostics
-Balance sheet challenges gave potential customers pause
*Concern was if Amarantus had financial difficult it could damage customer trials
Spin-off of Amarantus Diagnostics into Avant/Theranosticsallows for clean balance sheet and familiar services provider
Overall cell cycle biology expertise added bonus
Amarantus business development to work with Theranosticsto take over relationships
http://content.stockpr.com/amarantus/db/184/1...+FINAL.pdf
(6)
(1)